This is a material derisking event for ASPI's Silicon-28 commercialization pathway. Successful steady-state operation of 18 stages and a Q3 2026 commercial shipment target are concrete milestones beyond prior 'first samples' stage. Monitor for updates on remaining stages commissioning and any customer announcements that could confirm revenue timing — the three existing contracts suggest committed demand.
Price Chart
Executive Summary
ASP Isotopes announced it successfully restarted the first 18 stages (segments one and two) of its Silicon-28 enrichment facility in Pretoria, South Africa, after nine months of engineering enhancements to non-core components (valves, compressors, piping). The company expects initial commercial shipments of enriched Silicon-28 to U.S. customers in Q3 2026, building on three previously announced supply contracts and independent confirmation that earlier sample enrichment levels tracked theoretical calculations.
Key Facts
- First 18 stages of Silicon-28 enrichment facility successfully restarted and operated for over three weeks at target enrichment levels.
- Engineering modifications over the past nine months addressed non-core components (valves, compressors, piping); same enhancements to be applied to remaining stages.
- Initial commercial shipments of enriched Silicon-28 expected to commence in Q3 2026.
- Three commercial contracts for enriched Silicon-28 previously signed with U.S.-based customers.
- First samples shipped to a U.S. customer in August 2025; independent analysis confirmed enrichment levels tracked in line with theoretical calculations.
- Enriched Silicon-28 applications cited for quantum computing (qubit coherence) and next-gen semiconductor thermal management.
Financial Impact
No financial figures disclosed — revenue, contract values, and unit economics are not in the filing.
Risk Factors
- Remaining stages of the enrichment facility still require implementation of engineering modifications — no timeline given for full completion.
- Commercial production scale-up remains subject to operational, regulatory, and geopolitical risks in South Africa.
- Pre-revenue company with no disclosed contract values or revenue; financial viability depends on successful commercialization.
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 5 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 8-K Filing (Primary) | 0001193125-26-237916 |
| Document: aspi-ex99_1.htm | 0001193125-26-237916 |
| Document: 0001193125-26-237916-index-headers.html | 0001193125-26-237916 |
| Document: 0001193125-26-237916-index.html | 0001193125-26-237916 |
| Document: 0001193125-26-237916.txt | 0001193125-26-237916 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Oct 26, 2026 today | 8-K | $2.07 | awaiting T+5 | — | $2.03 (−2.18%) |
Oct 15, 2026 11d ago | 8-K | $2.21 $2.09 | ▼ −5.43% | ▼ −4.42% | $2.03 (−8.34%) |
Oct 2, 2026 24d ago | 8-K | $2.91 $2.65 | ▼ −8.93% | ▼ −10.10% | $2.03 (−30.39%) |
Sep 25, 2026 4w ago | 144 | $2.60 $2.93 | ▲ +12.69% | ▲ +11.49% | $2.03 (−22.09%) |
Sep 9, 2026 6w ago | 425 | $3.82 $3.15 | ▼ −17.54% | ▼ −16.44% | $2.03 (−46.97%) |
Sep 2, 2026 7w ago | 144 | $3.90 $3.31 | ▼ −15.13% | ▼ −13.98% | $2.03 (−48.06%) |
Aug 20, 2026 9w ago | 425 / 8-K | $3.95 $4.04 | ▲ +2.41% | ▲ +1.29% | $2.03 (−48.65%) |
Aug 18, 2026 9w ago | 8-K | $3.86 $4.00 | ▲ +3.63% | ▲ +3.83% | $2.03 (−47.52%) |
Aug 16, 2026 10w ago | Institutional Cluster | $4.02 $3.89 | ▼ −3.23% | ▼ −2.04% | $2.03 (−49.61%) |
Aug 5, 2026 11w ago | 425 | $4.10 $4.28 | ▲ +4.39% | ▲ +3.18% | $2.03 (−50.60%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers